Designing Chromane Derivatives as α2A-Adrenoceptor Selective Agonists via Conformation Constraint.
J Med Chem
; 67(13): 11435-11449, 2024 Jul 11.
Article
em En
| MEDLINE
| ID: mdl-38889119
ABSTRACT
Enhancing the selectivity of alpha2-adrenoceptor (α2A-AR) agonists remains an unresolved issue. Herein, we reported the design of an α2A-AR agonist using the conformation constraint method, beginning with medetomidine. The structure-activity relationship indicated that the 8-substituent of chromane derivatives exerted the most pronounced effect on α2A-AR agonistic activity. Compounds A9 and B9 were identified as the most promising, exhibiting EC50 values of 0.78 and 0.23 nM, respectively. Their selectivity indexes surpassed dexmedetomidine (DMED) by 10-80 fold. In vivo studies demonstrated that both A9 and B9 dose-dependently increased the loss of righting reflex in mice, with ED50 values of 1.54 and 0.138 mg/kg, respectively. Binding mode calculations and mutation studies suggested the indispensability of the hydrogen bond between ASP1283.32 and α2A-AR agonist. In particular, A9 and B9 showed no dual reverse pharmacological effect, a characteristic exhibited by DMED in α2A-AR activation.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Desenho de Fármacos
/
Cromanos
/
Receptores Adrenérgicos alfa 2
/
Agonistas de Receptores Adrenérgicos alfa 2
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article